The association between bisphosphonate therapy and osteonecrosis of the jaw was first reported in 2003, in patients with malignant disease who were being treated with large doses of intravenous bisphosphonates. Subsequently, possible cases of osteonecrosis of the jaw have been reported in a very small number of people taking oral bisphosphonates for osteoporosis; at the time of publication of its 'expert panel recommendations', the American Dental Association estimated that there were approximately 183 such cases worldwide. The word 'possible' is particularly apposite in the context of diagnosis of osteonecrosis of the jaw, since the disease is poorly characterized in terms of its clinical definition, natural history and pathogenesis. Of the cases reported, 170 were in people taking alendronate, 12 in people taking risedronate and one in a person taking ibandronate; 1 however, the association with alendronate in most cases does not necessarily imply a specific causal association with this drug but more likely reflects prescribing patterns of bisphosphonate therapy in osteoporosis. As Basu and Reid point out in their article on this condition in this issue of Menopause International, the small number of cases reported comprise only a miniscule proportion of the population taking these drugs for osteoporosis. According to the American Dental Association, the risk in this population is around 0.7 per 100,000 person-years of exposure to bisphosphonates.
Notwithstanding the very low risk of osteonecrosis of the jaw in people receiving bisphosphonates for osteoporosis, increasing awareness of the condition among both health professionals and patients has necessitated the development of guidelines or recommendations for use in clinical practice. The main issues that arise are:
• whether patients should routinely be counselled about the risk of developing osteonecrosis of the jaw before they start bisphosphonates • whether they should have a dental check-up before they start therapy • and whether bisphosphonates should be stopped if dental problems arise during treatment.
There is no robust evidence base to support recommendations in any of these areas and current guidelines are based on expert opinion only. Several position statements have recently been issued, mainly from the US, 1-3 and in May 2006 the Medicines and Healthcare products Regulatory Agency (MHRA) published guidance for health professionals in the UK. 4 Opinion is divided as to the need to discuss the potential risk of osteonecrosis of the jaw with all patients before they start treatment. If routine dental examination is recommended before treatment, as in the US, this discussion is implicit in the management plan. However, where dental examination is not routinely undertaken before treatment, a decision has to be taken as to whether information about this very rare adverse effect should be given to all patients. In some cases this decision has already been taken by patients, who will raise the issue themselves; in others it could be argued that it may raise anxiety unnecessarily and further decrease the already poor compliance and persistence with bisphosphonate therapy. A middle course, and that adopted by the MHRA, is to counsel only those who are likely to be at increased risk, for example patients with poor dental health, or those taking glucocorticoids or receiving chemotherapy for cancer. Dental examination and treatment, if appropriate, should be considered before such individuals start bisphosphonate therapy. The practicality of recommending routine dental examination in all patients also has to be considered; in the UK, this would inevitably delay the start of treatment by some months and compromise the potential benefits of prompt treatment in those at high risk of fracture.
There is currently no evidence to suggest whether withdrawal of bisphosphonate therapy affects the outcome of dental disease or intervention in those established on treatment. At present, none of the guidelines, including those produced by the MHRA, recommend that treatment should be stopped in these circumstances, in recognition of the fact that, because of the long half-life of bisphosphonates in bone, the prognosis for either dental or skeletal health is unlikely to be affected by short-term withdrawal. Nevertheless, J Compston Oral bisphosphonates and osteonecrosis of the jaw in clinical practice it is not uncommon for patients to be advised to stop bisphosphonate therapy when they develop dental problems and in such cases it may be appropriate to discuss alternative bone-protective treatments.
The advent of bisphosphonate therapy for osteoporosis has been a significant advance and many patients have benefited from its use. The MHRA document provides measured guidance that, while stressing the need for precautions in some patients, recognizes the strongly positive benefit-risk balance for the vast majority of individuals. Meanwhile, further clarification of the causes, clinical features and treatment of osteonecrosis of the jaw is a research priority and should enable more evidence-based preventive strategies to be developed.
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